Evidence map›Paper›PMID 27751590›Full record

ReviewGynecologic oncology2016

Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review.

Eric R Craig, Angelina I Londoño, Lyse A Norian, Rebecca C Arend

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gynecologic oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Metabolic risk factors of ovarian cancer: a review.JBRA assisted reproduction · 2022
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. One-Carbon Metabolism: Biological Players in Epithelial Ovarian Cancer.International journal of molecular sciences · 2018
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Eric R CraigSchool of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Angelina I LondoñoDepartment of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Lyse A NorianDepartment of Nutrition Sciences and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Rebecca C ArendDepartment of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: rarend@uabmc.edu.
University of Alabama at Birmingham · US

Funding

Obesity Affects Immunity to Kidney CancerR01CA181088 · NCI · UNIVERSITY OF IOWA · PI NORIAN, LYSE A · 2014 to 2018
$1.5M
Research Training Program in Basic and Translational OncologyT32CA183926 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BHATIA, RAVI · 2014 to 2018
$1.0M
NCI NIH HHS R01 CA181088NCI NIH HHS T32 CA183926
6 · The paper itself

Abstract

objectiveEpithelial ovarian cancer continues to be the deadliest gynecologic malignancy. Patients with both diabetes mellitus and obesity have poorer outcomes, yet research correlating metabolic abnormalities, such as metabolic syndrome, to ovarian cancer risk and outcomes is lacking. This article reviews the literature regarding metabolic derangements and their relationship to epithelial ovarian cancer, with a focus on potential mechanisms behind these associations.

methodsPubMed and Google Scholar were searched for articles in the English language regarding epithelial ovarian cancer, obesity, diabetes mellitus, and metabolic syndrome, with a focus on studies conducted since 1990.

resultsObesity, type II diabetes mellitus, and metabolic syndrome have been associated with poor outcomes in epithelial ovarian cancer. More studies investigating the relationship between metabolic syndrome and epithelial ovarian cancer are needed. A variety of pathologic factors may contribute to cancer risk in patients with metabolic derangements, including altered adipokine and cytokine expression, altered immune responses to tumor cells, and changes in pro-tumorigenic signaling pathways.

conclusionMore research is needed to examine the effects of metabolic syndrome on epithelial ovarian cancer risk and mortality, as well as the underlying pathophysiologies in patients with obesity, diabetes mellitus, and metabolic syndrome that may be targeted for therapeutic intervention.

Indexed as

AdipokinesCarcinoma, Ovarian EpithelialCytokinesDiabetes Mellitus, Type 2FemaleHumansInflammationMetabolic SyndromeNeoplasms, Glandular and EpithelialObesityOvarian NeoplasmsRisk FactorsSignal TransductionAdipokinesCytokinesDiabetes mellitusEpithelial ovarian cancerImmune suppressionMetabolic syndromeObesity

Identifiers

PMID27751590
PMCPMC5689410
OpenAlexW2536764426

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.